Skip to main navigation Skip to search Skip to main content

Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial

  • Alexander MM Eggermont
  • , Michal Kicinski
  • , Christian U. Blank
  • , Mario Mandala
  • , Georgina V. Long
  • , Victoria Atkinson
  • , Stéphane Dalle
  • , Andrew Haydon
  • , Andrey Meshcheryakov
  • , Adnan Khattak
  • , Matteo S. Carlino
  • , Shahneen Sandhu
  • , James Larkin
  • , Susana Puig
  • , Paolo A. Ascierto
  • , Piotr Rutkowski
  • , Dirk Schadendorf
  • , Marye Boers-Sonderen
  • , Anna Maria Di Giacomo
  • , Alfonsus JM van den Eertwegh
    • Jean Jacques Grob, Ralf Gutzmer, Rahima Jamal, Alexander C.J. van Akkooi, Paul Lorigan, Dmitri Grebennik, Clemens Kreplere, Sandrine Marreaud, Stefan Suciu, Caroline Robert

    Research output: Contribution to journal › Article › peer-review

    60   Link opens in a new tab Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial'. Together they form a unique fingerprint.
    Sort by

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Neuroscience